Steven W. Yancey

MedicineSocial Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial”.

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial

Journal of Allergy and Clinical Immunology(2020)10.1016/j.jaci.2020.08.037

N/A

4.7DataRank · unranked

206 citations

Jean‐Emmanuel Kahn, Marc E. Rothenberg, Andrew J. Wardlaw, Amy D. Klion, Suyong Yun Kirby +7 more

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype

ACR Open Rheumatology(2023)10.1002/acr2.11571

N/A

0DataRank · unranked

31 citations

David Jayne, Bernhard Hellmich, Jane H. Bentley, Jonathan Steinfeld, Steven W. Yancey +7 more

Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics

ERJ Open Research(2023)10.1183/23120541.00509-2023

N/A

0DataRank · unranked

20 citations

Benjamin Terrier, Bernhard Hellmich, Paneez Khoury, Lee Baylis, Jane H. Bentley +6 more